Acasă › Cancer pulmonar cu celule non-pătrate › Michigan › Ann Arbor
Studii clinice pentru Cancer pulmonar cu celule non-pătrate în Ann Arbor, MI
26 studii pentru Cancer pulmonar cu celule non-pătrate caută participanți în și în jurul orașului Ann Arbor (în aproximativ 50 km). Deschideți un studiu pentru a vedea criteriile de eligibilitate și cum să contactați echipa de cercetare.
Text oficial al studiului (în engleză)
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
În curs de recrutareFaza 3
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
- Huron Gastroenterology PC, Ypsilanti · La 7 mi distanță
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus, Ypsilanti · La 7 mi distanță
- și încă 4
A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment
În curs de recrutareFaza 2
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus, Ypsilanti · La 7 mi distanță
- Chelsea Hospital, Chelsea · La 15 mi distanță
- și încă 3
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
În curs de recrutareFaza 3
- University of Michigan Rogel Cancer Center, Ann Arbor
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus, Ypsilanti · La 7 mi distanță
- Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital, Chelsea · La 15 mi distanță
- și încă 2
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
În curs de recrutareFaza 3
- Trinity Health Ann Arbor Hospital, Ann Arbor
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
În curs de recrutareFaza 2
- University of Michigan Health System, Ann Arbor
- Trinity Health St Joseph Mercy Ann Arbor, Ypsilanti · La 7 mi distanță
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
În curs de recrutareFaza 2
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
- Huron Gastroenterology PC, Ypsilanti · La 7 mi distanță
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus, Ypsilanti · La 7 mi distanță
- și încă 4
A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)
În curs de recrutareFaza 1
- University of Michigan Health Systems, Ann Arbor
A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
În curs de recrutareFaza 1/2
- University of Michigan Medical School Rogel Cancer Center, Ann Arbor
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
În curs de recrutareFaza 3
- Clinical Study Site, Ann Arbor
A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
În curs de recrutareFaza 2
- University of Michigan, Ann Arbor
A Phase 1/1b Study of IAM1363 in HER2 Cancers
În curs de recrutareFaza 1
- University of Michigan, Ann Arbor
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
În curs de recrutareFaza 3
- University of Michigan, Ann Arbor
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
În curs de recrutareFaza 3
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor ( Site 9552), Ypsilanti · La 7 mi distanță
Gilteritinib for the Treatment of ALK NSCLC
În curs de recrutareFaza 1
- University of Michigan Comprehensive Cancer Center, Ann Arbor
Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
În curs de recrutareFaza 1
- University of Michigan Comprehensive Cancer Center Michigan Medicine /ID# 252010, Ann Arbor
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
În curs de recrutareFaza 2
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
- Huron Gastroenterology PC, Ypsilanti · La 7 mi distanță
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus, Ypsilanti · La 7 mi distanță
- și încă 4
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
În curs de recrutareFaza 2
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus, Ypsilanti · La 7 mi distanță
- Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital, Chelsea · La 15 mi distanță
- și încă 1
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
În curs de recrutareFaza 2/3
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus, Ypsilanti · La 7 mi distanță
- Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital, Chelsea · La 15 mi distanță
- Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton · La 18 mi distanță
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
În curs de recrutareFaza 2
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
- Huron Gastroenterology PC, Ypsilanti · La 7 mi distanță
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus, Ypsilanti · La 7 mi distanță
- și încă 4
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
În curs de recrutareFaza 1/2
- University of Michigan, Ann Arbor
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
În curs de recrutareStudiu observațional
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
Repositioning Immunotherapy in VetArans With Lung Cancer
În curs de recrutareFaza 2
- VA Ann Arbor Healthcare System, Ann Arbor, MI, Ann Arbor
A Study of Trastuzumab Deruxtecan in People With Non-Small Cell Lung Cancer
În curs de recrutareFaza 2
- University of Michigan (Data Collection Only), Ann Arbor
Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy
În curs de recrutare
- VA Ann Arbor Healthcare System, Ann Arbor, MI, Ann Arbor
EZH2 Inhibitor, Tulmimetostat, and PD-1 Blockade for Treatment of Advanced Non-small Cell Lung Cancer
În curs de recrutareFaza 1/2
- VA Ann Arbor Healthcare System, Ann Arbor, MI, Ann Arbor
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
În curs de recrutareStudiu observațional
- Massive Bio SYNERGY-AI site, Ann Arbor
Studii pentru Cancer pulmonar cu celule non-pătrate în alte orașe
- Houston, TX145 studii
- New York City, NY121 studii
- Arlington, VA104 studii
- Nashville, TN97 studii
- Boston, MA90 studii
- Los Angeles, CA87 studii
- St. Louis, MO73 studii
- Chicago, IL61 studii
- Baltimore, MD60 studii
- San Antonio, TX59 studii
- Columbus, OH57 studii
- Washington, DC55 studii
Alte studii în Ann Arbor
- Cancer de sân27 studii
- Cancer de prostată27 studii
- Cancer (toate tipurile)25 studii
- Cancer pulmonar23 studii
- Cancer colorectal23 studii
- Insuficiență cardiacă22 studii
- Leucemie mieloasă acută17 studii
- Boli cardiovasculare16 studii
- Cancer pancreatic14 studii
- Melanom12 studii
- Accident vascular cerebral12 studii
- Carcinom cu celule scuamoase de cap și gât12 studii
Sursă: ClinicalTrials.gov, date preluate la 6 oct. 2026. Fiecare studiu are propriile criterii de eligibilitate; echipa de cercetare decide cine poate participa.